Related Experiment Video

Updated: Jul 10, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Targeting the epidermal growth factor receptor in metastatic colorectal cancer

Kimmie Ng1, Andrew X Zhu

  • 1Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.

Critical Reviews in Oncology/Hematology
|November 17, 2007
PubMed

Insights

Metastatic colorectal cancer (CRC) treatment shows poor survival. Epidermal growth factor receptor (EGFR) inhibitors offer clinical benefits, with ongoing research into novel strategies and predictive biomarkers for improved efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic colorectal cancer (CRC) has a poor prognosis, with a 5-year survival rate under 10% despite treatment advances.
  • Epidermal growth factor receptor (EGFR) pathway is implicated in CRC pathogenesis.
  • Monoclonal antibodies targeting EGFR demonstrate clinical benefit in refractory settings, often combined with chemotherapy, and exhibit tolerable toxicity.

Purpose of the Study:

  • To review the role of the EGFR pathway in colorectal cancer development.
  • To discuss current data supporting the use of cetuximab and panitumumab for CRC treatment.
  • To explore clinical trials of EGFR tyrosine kinase inhibitors and novel targeting strategies in CRC.

Main Methods:

  • Literature review of existing data on EGFR pathway in CRC.
  • Analysis of clinical trial outcomes for anti-EGFR therapies.
  • Examination of emerging research on molecular predictors of response.

Main Results:

  • EGFR inhibitors like cetuximab and panitumumab have shown efficacy in metastatic CRC.
  • Combination therapies and novel EGFR-targeting strategies are under investigation.
  • Identifying molecular predictors is crucial for optimizing anti-EGFR therapy response.

Conclusions:

  • Targeting the EGFR pathway is a key strategy in metastatic colorectal cancer treatment.
  • Further research is needed to enhance efficacy and identify predictive biomarkers for anti-EGFR agents.
  • Personalized medicine approaches utilizing molecular predictors may improve outcomes in CRC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...